An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines-Reference-Cited by-同舟云学术

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines

Published:2017-12-22 Issue:3 Volume:65 Page:e26887
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Dionne Francois¹^ORCID,Aminkeng Folefac²³⁴,Bhavsar Amit P.⁵,Groeneweg Gabriella²³⁶,Smith Anne²³⁶,Visscher Henk²⁴,Rassekh Shahrad Rod²⁷,Ross Colin²⁸,Carleton Bruce²³⁶

Affiliation:

1. Centre for Clinical Epidemiology and Evaluation; Vancouver British Columbia Canada

2. BC Children's Hospital Research Institute (formerly known as the Child and Family Research Institute); Vancouver British Columbia Canada

3. Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine; University of British Columbia; Vancouver British Columbia Canada

4. Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics; University of British Columbia; Vancouver British Columbia Canada

5. Department of Medical Microbiology and Immunology; University of Alberta; Edmonton Alberta Canada

6. Pharmaceutical Outcomes Programme; BC Children's Hospital; Vancouver British Columbia Canada

7. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation; Department of Pediatrics, University of British Columbia; Vancouver British Columbia Canada

8. Faculty of Pharmaceutical Sciences; University of British Columbia; Vancouver British Columbia Canada

Funder

Genome British Columbia

Canadian Foundation for Innovation

Michael Smith Foundation for Health Research

University of British Columbia and Pfizer

Canadian Institutes of Health Research

Provincial Health Services Authority

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health